Lyn­dra Ther­a­peu­tics eyes $180M Se­ries D for po­ten­tial 2026 launch of once-week­ly schiz­o­phre­nia med

With a Phase III tri­al now un­der­way for a once-week­ly, long-act­ing ver­sion of the an­tipsy­chot­ic med risperi­done, Lyn­dra Ther­a­peu­tics is eye­ing a large Se­ries D …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER